Skip to content
AnalystLens

Charles River Laboratories International Quarterly Report for Q1 Ended Mar 28, 2026

Filing Date
Filed May 7, 2026
Period End
March 28, 2026
Security
CRL
In the record · 2016–202610-K1110-Q338-K117

CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 117 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Jun ’16Jun ’16
  2. Deal closed8-K · May ’19May ’19
  3. Leadership change8-K · May ’21May ’21
  4. Leadership change8-K · May ’25May ’25

Summary

Summary of the 10-Q filed May 7, 2026. Cited figures are marked; the original filing is the authoritative source.

Charles River Laboratories International, Inc. reported a first-quarter 2026 net loss attributable to common shareholders of $14.8 milliona ($0.30 per diluted share), compared with net income of $25.5 million ($0.50 per diluted share) in the prior-year quarter.

The decline was driven principally by a $118.0 millionb pre-tax loss on assets held for sale tied to the CDMO and Cell Solutions Divestiture, which was completed on May 6, 2026. Total revenue rose $11.7 million, or 1.2%, to $995.8 million, led by Manufacturing (up 6.8%) and DSA (up 0.7%), partly offset by RMS (down 2.2%). Operating income increased 60.6% to $119.9 million, helped by a $38.5 million pre-tax gain on the sale of Wilmington, Massachusetts assets and the absence of prior-year accelerated amortization.

Cash flow and balance sheet activity were significant. Operating cash flow fell to $41.1 millionc from $171.7 million, mainly due to higher annual incentive bonus payments. The company spent $405.0 million on acquisitions, primarily the Cambodian NHP Supplier, which closed January 14, 2026 for a preliminary purchase price of $507.3 million.

Long-term debt, net rose to $2.66 billiond from $2.14 billion, with the revolving facility balance increasing to $1.17 billion. The company repurchased $200.0 million of stock during the quarter and had $800.0 million remaining under its $1.0 billion authorization.

Management stated that DSA backlog was consistent at $1.9 billion and that the client base remains cautious in spending, principally in DSA. The company also disclosed a cybersecurity incident involving unauthorized access to certain information systems, which it said had not had a material impact as of the filing date, and noted ongoing securities and derivative litigation related to non-human primate importation disclosures.

Key Highlights

  1. Net loss attributable to common shareholders of $14.8 million, or $(0.30) per diluted share, versus net income of $25.5 million, or $0.50 per diluted share, in Q1 2025
  2. Total revenue of $995.8 million, up $11.7 million or 1.2%; Manufacturing revenue up 6.8%, DSA up 0.7%, RMS down 2.2%
  3. Operating income of $119.9 million, up 60.6%, with operating margin of 12.0% versus 7.6%, aided by a $38.5 million pre-tax gain on Wilmington, Massachusetts asset sale
  4. $118.0 million pre-tax loss on assets held for sale for the CDMO and Cell Solutions Divestiture, which was completed May 6, 2026, and drove the other expense, net of $124.1 million
  5. Operating cash flow of $41.1 million versus $171.7 million, primarily due to higher annual incentive bonus payments; $405.0 million spent on acquisitions, mainly the Cambodian NHP Supplier
  6. Long-term debt, net and finance leases increased to $2.66 billion from $2.14 billion, with the revolving facility at $1.17 billion; $200.0 million of stock repurchased, leaving $800.0 million under the $1.0 billion program
  7. Company disclosed a social engineering cyber incident; it stated the incident had not had a material impact as of the filing date and that the activity was contained

Financial Statements

Q1 FY2026 against Q1 FY2025

Line itemQ1 FY2026Q1 FY2025Change
Revenue$995.83M$984.17M+1.2%
SG&A Expenses$159.42M$177.80M−10.3%
Operating Income$119.90M$74.67M+60.6%
Net Income-$14.84M$25.47M−158.3%
EPS (Basic)$-0.30$0.50−160.0%
EPS (Diluted)$-0.30$0.50−160.0%
Shares Outstanding (Basic)48.95M50.68M−3.4%
Shares Outstanding (Diluted)48.95M50.85M−3.7%

Frequently Asked Questions

  1. Why did Charles River report a net loss this quarter when operating income increased?

    The net loss was driven by other expense, net of $124.1 million, which included a $118.0 million pre-tax loss on assets held for sale related to the CDMO and Cell Solutions Divestiture. Operating income rose to $119.9 million from $74.7 million, helped by a $38.5 million gain on the Wilmington, Massachusetts asset sale and lower accelerated amortization versus the prior year.

  2. How did the company's segments perform?

    Manufacturing revenue rose 6.8% to $190.5 million, with operating income of $46.8 million versus a loss of $8.6 million a year earlier. DSA revenue rose 0.7% to $596.9 million, and operating income rose 10.6% to $103.9 million. RMS revenue fell 2.2% to $208.4 million, though operating income rose 14.1% to $49.8 million.

  3. What acquisitions and divestitures did the company make?

    The company acquired the Cambodian NHP Supplier on January 14, 2026 for a preliminary purchase price of $507.3 million, and completed the acquisition of an additional 79% stake in PathoQuest SAS on April 17, 2026 for a preliminary price of about $60.0 million. It agreed to sell certain European Discovery Services businesses to IQVIA for $145.0 million, expected to close in the second quarter of 2026, and completed the sale of its CDMO and Cell Solutions businesses to GI Partners on May 6, 2026.

  4. How is the company's liquidity and capital allocation position?

    Cash and cash equivalents were $191.8 million at March 28, 2026. The company drew $912.5 million in new debt proceeds and repaid $355.7 million, with net revolving credit facility proceeds of $557.7 million. It repurchased $200.0 million of stock under its $1.0 billion program, leaving $800.0 million remaining, and management stated it believes existing funds and financing resources are sufficient for the foreseeable future.

  5. What legal and operational risks were disclosed?

    The filing describes a putative securities class action filed May 19, 2023 and two derivative lawsuits, all related to disclosures about non-human primate importation, which the company believes are without merit and cannot reasonably estimate exposure for. It also disclosed a recent cybersecurity incident in which an attacker obtained employee credentials through social engineering; the company stated it had not had a material impact on its financial systems, operations or financial condition as of the filing date.